TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05614739: FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alteratio

Sponsor: Eli Lilly and Company · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 677 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$7,037,184

Rescue Site Savings

+$4,649,568

Unlock Full NCT05614739 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05614739 Rescue Dossier →